問卷

TPIDB > Principal Investigator

Principal Investigator


China Medical University Hospital (在職)

Division of Thoracic Medicine

Division of Hematology & Oncology

Division of General Internal Medicine

更新時間:2023-09-19

涂智彥Tu, Chih-Yen
  • Principal Investigator
  • Clinical Trial Experience (year) 12 years 9 個月
  • D7855@mail.cmuh.org.tw

篩選

List

168Cases

2008-03-01 - 2010-06-30

Phase II/III

Phase IIb/III randomized, double-blind trial of BIBW 2992 plus best supportive care (BSC) versus placebo plus BSC in non-small cell lung cancer patients failing erlotinib or gefitinib.
  • Condition/Disease

    Non-small cell lung cancer

  • Test Drug

    BIBW 2992

Participate Sites
7Sites

Terminated7Sites

2007-09-01 - 2009-11-30

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2011-12-07 - 2014-06-30

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2015-12-01 - 2016-12-23

Phase III

An Open-label, Randomized, Phase 3 Study of Nivolumab or Chemotherapy in Subjects with Relapsed Small-cell Lung Cancer after Platinum-based Fist Line Chemotherapy
  • Condition/Disease

    Small-cell Lung Cancer

  • Test Drug

    Nivolumab

Participate Sites
4Sites

Terminated3Sites

2015-01-01 - 2026-12-31

Phase III

RANDOMIZED, MULTICENTER, PHASE III, OPEN-LABEL STUDY OF ALECTINIB VERSUS CRIZOTINIB IN TREATMENT-NAÏVE ANAPLASTIC LYMPHOMA KINASE−POSITIVE ADVANCED NON−SMALL CELL LUNG CANCER
  • Condition/Disease

    ADVANCED NON−SMALL CELL LUNG CANCER

  • Test Drug

    RO5424802

Participate Sites
6Sites

Recruiting4Sites

Terminated2Sites

2015-02-25 - 2025-12-31

Phase III

A PHASE III PROSPECTIVE DOUBLE BLIND PLACEBO CONTROLLED RANDOMIZED STUDY OF ADJUVANT MEDI4736 IN COMPLETELY RESECTED NON-SMALL CELL LUNG CANCER
  • Condition/Disease

    COMPLETELY RESECTED NON-SMALL CELL LUNG CANCER

  • Test Drug

    MEDI4736

Participate Sites
13Sites

Not yet recruiting2Sites

Recruiting3Sites

Terminated8Sites

2014-02-14 - 2020-08-28

Phase III

A Phase 3 Randomized Double-blind Study Comparing TR-701 FA and Linezolid in Ventilated Gram-positive Nosocomial Pneumonia
  • Condition/Disease

    Ventilated Gram-positive Nosocomial Pneumonia

  • Test Drug

    TR-701 FA for Injection

Participate Sites
5Sites

Terminated4Sites

Study ended1Sites

涂智彥
China Medical University Hospital

Division of Thoracic Medicine